tbuckley/cabot-search huggingface dataset:
Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients
Authors: Yi Lisa Hwa, Martha Q. Lacy, Morie A Gertz, Francis Buadi, S. Vincent Rajkumar, Shaji Kumar, Prashant Kapoor, Ronald S. Go, Suzanne R Hayman, Yi Lin, John A. Lust, David Dingli, Stephen J. Russell, Wilson I Gonsalves, Angela Dispenzieri
Journal: Blood (2014)
CSIG-02. ANGIOTENSIN SIGNALLING IN GBM: AT2R AS A NOVEL THERAPEUTIC TARGET
Authors: Alexander Renziehausen, Jennifer Eschbacher, Kevin O’Neill, Andreas Tzakos, Tim Crook, Nelofer Syed
Journal: Neuro-Oncology (2016)

Locally expressed angiotensin II type 1 and type 2 receptors (AT1R and AT2R respectively) of the renin-angiotensin system have been implicated in cancer progression. While the involvement of AT1R has been well studied, the role of AT2R in cancer is largely unknown. The aim of this study is to investigate the influence of angiotensin signalling on the growth, migration and induction of angiogenesis in GBM, as well as determine whether commonly used drugs targeting angiotensin signalling to manage blood pressure have the potential to be repurposed as adjuvant therapies for GBM. GBM cell lines, both primary and established, were profiled for expression of AT1R and AT2R by qPCR and pyrosequencing. The antihypertensive drug Losartan and the AT2R antagonist PD123319 were used alone or in combination with the ligand angiotensin II in various assays. Colorimetric proliferation assays were used to assess the impact on growth and wound healing assays to assess migration, a determinant of GBM invasiveness. In addition, the induction of angiogenesis was also examined using conditioned media from GBM cells and analysing the effect on proliferation, migration and tube formation of the brain microvascular endothelial cell line hCMEC/D3. Gene expression changes downstream of receptor inhibition were analysed by qPCR. Inhibition of AT1R signalling via Losartan had no effect on the growth of GBM whereas inhibition of AT2R with PD123319 significantly reduced GBM cell proliferation, migration and the induction of angiogenesis. This effect was further enhanced by simultaneous treatment with Losartan and was accompanied by differential expression of downstream genes. Our data suggest that AT2R rather than AT1R is the main receptor promoting GBM cell growth, migration and the induction of angiogenesis. Therefore, inhibition of AT2R signalling could have potential in the treatment of GBM both alone and in combination with AT1R inhibition.
MS4A3 Marks Early Myeloid Differentiation in Human Hematopoiesis
Authors: Tomohiko Ishibashi, Takafumi Yokota, Yusuke Satoh, Takao Sudo, Yukiko Doi, Natsuko Fujita, Yasuhiro Nagate, Yuri Hamanaka, Keiko Matsui, Akira Tanimura, Michiko Ichii, Norimitsu Saitoh, Sachiko Ezoe, Hirohiko Shibayama, Kenji Oritani, Yuzuru Kanakura
Journal: Blood (2014)
Present status and perspective of percutaneous transluminal coronary angioplasty from the viewpoint of short and long term results. Comparative study of the results of PTCA and CABG procedure.
Authors: Yoshimasa Yabe, Hisashi Komatsu, Tadanori Aizawa
Journal: Circulation (1987)

Balloon technology has advanced to incorporate the skills of angioplasters while efforts to enhance their skills continue. These factors have contributed to the expansion of percutaneous transluminal coronary angioplasty (PTCA) indications. We have analyzed the comparison of short and long term results between PTCA and CABG revascularization procedures. In the development of revascularization procedures, one graft surgery has significantly declined in use since 1983 (2 years after the start of PTCA) while there has been an increase of multi graft surgery (more than 2 grafts). On the other hand, PTCA has showed a linear increase since 1982 and reached 160 cases in 1985. The growth of complex angioplasty other than PTCA for single discrete lesions is parallel to that of PTCA and has been used in 44% of overall cases. The growth curve of angioplasty crossed over that of revascularization surgery in 1983. PTCA was successful in 246 patients out of 300 overall cases representing 88% success rate and in 340 lesions representing an 81% success. For CABG the patency rate was 89.5% which means a out of 638 grafts were successful. PTCA was conducted in 137 cases with multiple lesion. That data could be interpreted as mean patient success of 120/137, lesion success was 196/265 with a success rate of 88% and 73%, respectively. Primary results in 284 multi CABG cases were good with a patency rate of 91% (487 patent grafts out of 536 anastomoses). However, in-hospital deaths were 3.5% higher (10 cases with CABG group). The effective dilatation of high-grade organic lesion was found to be closely related to the improvement of clinical symptoms and a marked decrease in incidence of ergonovine induced spasms at the angioplasty site in patients with vasospastic angina (VSA). Thus PTCA can be accepted as an alternative therapy to CABG in VSA. In the long term follow up, work load response parameters such as exercise time, % predicted HR, PRP, Mets and the modified treadmill exercise scores improved significantly after the successful PTCA.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Authors: David Cameron, Martine J Piccart-Gebhart, Richard D Gelber, Marion Procter, Aron Goldhirsch, Evandro de Azambuja, Gilberto Castro, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Nedal Al-Sakaff, Sabine Lauer, Eleanor McFadden, Brian Leyland-Jones, Richard Bell, Mitch Dowsett, Christian Jackisch
Journal: The Lancet (2017)
Cutaneous squamous cell carcinoma: an epidemiological review
Authors: A.C. Green, C.M. Olsen
Journal: British Journal of Dermatology (2017)

Cutaneous squamous cell carcinoma (SCC) is a common cancer in white populations and its disease burden is often substantially underestimated. SCC occurs more often in men than women and increases dramatically with age; those affected often develop multiple primaries over time, which increases the burden. The main external cause is solar ultraviolet radiation (UVR), with immunosuppression being the other established risk factor, shown by the high SCC rates in organ transplant recipients. Sunbed use and certain genetic disorders and medical conditions are also associated with SCC, while associations with human papillomavirus infection and high bodyweight are not established. The presence of actinic keratoses (AKs) on sun‐damaged skin is one of the strongest predictors of SCC in unaffected people and a very small proportion of AKs are SCC precursors, although the true rate of malignant transformation of AKs is unknown. The mainstay of SCC prevention is protection of the skin from undue sun exposure by use of clothing cover and sunscreen during summer or in sunny places. Educational, behavioural and multicomponent interventions directed at individuals ranging from parents of newborns, to school children and adolescents, to outdoor workers, have repeatedly been shown to be effective in improving sun‐protective behaviours. Health policies can facilitate SCC prevention by setting standards for relevant behaviours to reduce UVR exposure, for example, by legislated restriction of the tanning industry. Skin cancer prevention initiatives are generally highly cost‐effective and public investment should be encouraged to control the growing public health problems caused by SCC.
Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine
Authors: J. Ventriglia, A. Petrillo, M. Huerta, M.M. Laterza, B. Savastano, V. Gambardella, G. Tirino, L. Pompella, A. Diana, A. Febbraro, T. Troiani, M. Orditura, A. Cervantes, F. Ciardiello, F. De Vita
Journal: Annals of Oncology (2016)
Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Mandy L.Y. Sin, Kathleen E. Mach, Rahul Sinha, Fan Wu, Dharati R. Trivedi, Emanuela Altobelli, Kristin C. Jensen, Debashis Sahoo, Ying Lu, Joseph C. Liao
Journal: Clinical Cancer Research (2017)

Purpose: The majority of bladder cancer patients present with localized disease and are managed by transurethral resection. However, the high rate of recurrence necessitates lifetime cystoscopic surveillance. Developing a sensitive and specific urine-based test would significantly improve bladder cancer screening, detection, and surveillance.Experimental Design: RNA-seq was used for biomarker discovery to directly assess the gene expression profile of exfoliated urothelial cells in urine derived from bladder cancer patients (n = 13) and controls (n = 10). Eight bladder cancer specific and 3 reference genes identified by RNA-seq were quantitated by qPCR in a training cohort of 102 urine samples. A diagnostic model based on the training cohort was constructed using multiple logistic regression. The model was further validated in an independent cohort of 101 urines.Results: A total of 418 genes were found to be differentially expressed between bladder cancer and controls. Validation of a subset of these genes was used to construct an equation for computing a probability of bladder cancer score (PBC) based on expression of three markers (ROBO1, WNT5A, and CDC42BPB). Setting PBC = 0.45 as the cutoff for a positive test, urine testing using the three-marker panel had overall 88% sensitivity and 92% specificity in the training cohort. The accuracy of the three-marker panel in the independent validation cohort yielded an AUC of 0.87 and overall 83% sensitivity and 89% specificity.Conclusions: Urine-based molecular diagnostics using this three-marker signature could provide a valuable adjunct to cystoscopy and may lead to a reduction of unnecessary procedures for bladder cancer diagnosis. Clin Cancer Res; 23(14); 3700-10. ©2017 AACR.
Prevalence and severity of fatigue in castration resistant prostate cancer in Spain: VITAL study
Authors: L. Martínez-Piñeiro, A. Rodríguez Antolín, M.E. Jiménez Romero, J.B. García Ramos, D. Lopez Bellido, P. Ruiz Gracia, A. Garcia Garcia-Porrero, F. Gomez Veiga
Journal: Annals of Oncology (2016)
An “Endothelialized” Microfluidic System That Distinguishes Procoagulant Mechanisms in Arterial and Venous Thrombosis
Authors: Byungwook Ahn, Yumiko Sakurai, David R Myers, Yongzhi Qiu, Elaissa Hardy, Reginald Tran, Robert Mannino, Alisa S. Wolberg, Wilbur Lam
Journal: Blood (2012)
Hypertension (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU).
Authors: S. George, T. Lechner, S. Li, D. P. Cohen, G. D. Demetri
Journal: Journal of Clinical Oncology (2011)

38 Background: HTN is a class effect of VEGF signaling pathway inhibitors. SU is a multitargeted inhibitor of VEGFRs and other receptor tyrosine kinases. Associations between SU-induced HTN and efficacy endpoints (OS, PFS, TTP, and ORR) in pts with imatinib-resistant/intolerant GIST from 2 prospective clinical trials were investigated retrospectively. Methods: This analysis included pooled data from 319 pts who received SU and had post-baseline blood pressure (BP) data available. Tumor response data were based on investigator assessments. Most pts (87%) received SU 50 mg/d on the standard 4-wk-on/2-wk-off schedule. BP was measured on the first and last day of dosing in each treatment cycle at a minimum. HTN was defined as max or mean SBP ≥ 140 or DBP ≥ 90 mmHg. OS, PFS, and TTP were estimated by Kaplan—Meier methods and compared between pts with vs. without HTN using the log-rank test. The influence of prognostic risk factors was analyzed using a Cox proportional hazards model. Results: 233 and 187 pts (73% and 59%) had ≥ 1 HTN episode as defined by max SBP and DBP, respectively. Efficacy results significantly favored pts who developed HTN on SU based on max SBP or DBP (eg, median OS for pts with HTN [max SBP] was 89.4 weeks vs. 53.1 weeks for pts without HTN [p = 0.0001]). Using HTN onset as a time-dependent covariate, HTN defined by max DBP was a significant predictor of prolonged TTP and PFS, and HTN defined by both max SBP and DBP was a significant predictor of prolonged OS (p &lt; 0.05). In multivariate analysis, HTN defined by max SBP or DBP was a significant independent predictor of improved OS, PFS, and TTP (p &lt; 0.0001). Analysis of any-grade and grade ≥3 cerebrovascular, ocular, cardiac, and renal AEs in pts with/without HTN is ongoing and will be presented. Clinical outcomes were not compromised in pts treated with anti-HTN medications. Conclusions: SU-associated HTN was significantly and independently associated with improved clinical outcomes, supporting the hypothesis that HTN is a biomarker for antitumor efficacy in pts with GIST treated with SU. Serial BP monitoring and standard use of anti-HTN medications, which were not shown to compromise efficacy, are recommended during SU therapy. [Table: see text]
Endoscopic therapy of appendicular bleeding complicated by shock
Authors: José Rodrigues, Joana Carmo, Liliana Carvalho, Miguel Bispo, Pedro Barreiro, Cristina Chagas
Journal: Endoscopy (2017)

A 57-year-old man, who was receiving antiplatelet therapy with acetylsalicylic acid for ischemic heart disease and had a recently diagnosed stage IV pulmonary adenocarcinoma (with liver and bone metastases), presented with hemorrhagic shock due to painless hematochezia. Total colonoscopy revealed active bleeding from the ileocecal appendix ([Fig. 1 a]). Initially epinephrine was injected at the appendicular base, but the bleeding was ongoing. Endoscopic therapy with hemostatic spray (Hemospray; Cook Medical, Winston-Salem, North Carolina, USA) was tried, with the achievement of immediate hemostasis ([Fig. 1 b, c]; [Video 1]). No recurrent bleeding was reported during the follow-up period (3 months).
IMST-04. IMAGING INFLAMMATORY CELL FUNCTION USING 13C MAGNETIC RESONANCE SPECTROSCOPY OF HYPERPOLARIZED 6-13C-LABELED ARGININE
Authors: Chloe Najac, Myriam M. Chaumeil, Gary Kohanbash, Caroline Guglielmetti, Jeremy Gordon, Hideho Okada, Sabrina M. Ronen
Journal: Neuro-Oncology (2016)

Inflammation is now recognized as an important hallmark of cancer, and immunotherapies offer a promising therapeutic approach. In particular, myeloid-derived suppressor cells (MDSCs) are highly prevalent inflammatory cells that play a key role in tumor development and are considered as potential therapeutic targets in the treatment of glioblastoma. MDSCs promote tumor growth by blocking T-cell-mediated anti-tumoral immune response through depletion of arginine that is essential for T-cell proliferation. To deplete arginine, MDSCs express high levels of arginase, the enzyme that catalyzes the breakdown of arginine into urea and ornithine. However, currently, there are no non-invasive imaging methods that can monitor MDSC function or arginase activity, limiting our ability to assess the efficacy of MDSC-targeting immunotherapies. Hyperpolarized 13C magnetic resonance spectroscopy (MRS) is a novel non-invasive imaging method that can monitor metabolism within seconds. The objective of this study was to use this new method and image arginase activity by monitoring the fate of hyperpolarized 6-13C-labeled arginine, a previously unexplored imaging probe. First we demonstrated that 6-13C-labeled arginine can be hyperpolarized, and that its MRS-detectable metabolism to urea is linearly correlated with arginase concentration in vitro. Then we investigated cells. Bone marrow (BM) cells isolated from Balb/c mice were cultured with cytokines. At day 4 cells were separated into two groups: control BM cells and MDSCs, generated by treating BM cells with interleukin-13. Up-regulation of arginase concentration in MDSCs was confirmed using a spectrophotometric assay. Then, we demonstrated that we were able to detect a statistically significant increase in the production of hyperpolarized 13C-labeled urea in MDSCs when compared to control BM cells. This confirmed the utility of hyperpolarized 13C MRS with 6-13C-labeled arginine as an imaging approach for monitoring arginase expression in cells. This method could be used to image tumoral MDSC function and its inhibition following MDSC-targeted immunotherapies.
Abnormal Medullary Lesions in Appendicular Skeletons Detected by Whole Body Low-Dose Multidetector CT Associated with Higher Tumor Burden and Poorer Prognosis in Patients with Myeloma
Authors: Yuki Nishida, Tomotaka Ugai, Kenji Tsuda, Hiroki Sugihara, Masayuki Yamakura, Masami Takeuchi, Kosei Matsue
Journal: Blood (2012)
Comorbidity and nutritional factors influence on bioradiotherapy (BRT) outcome in head and neck squamous cell carcinoma (HNSCC) patients
Authors: M. Oliva, M. Taberna, A.J. Rullan Iriarte, M. Bergamino, A. Rovira, R. Montal, L. Hurtos, L. Arribas, E. Vilajosana, A. Lozano, V. Navarro, S. Vazquez, M. Maños, R. Mesía
Journal: Annals of Oncology (2016)
Potential role of PLR and NLR in clinical decision making in locally advanced breast cancer
Authors: M. De Lisa, M. Pistelli, Z. Ballatore, B. Lucia, A. Pagliacci, S. Matteo, C. Luca, H. Tahani, N. Battelli, E. Maccaroni, R. Bracci, A. Santinelli, R. Berardi
Journal: Annals of Oncology (2016)
5-fluorouracil degradation rate (5-FU-DR) as a new toxicity predictive biomarker for adjuvant FOLFOX in colorectal cancer (CRC) patients
Authors: C.E. Onesti, A. Botticelli, F. Mazzuca, A. Milano, A. Romiti, M. Roberto, R. Falcone, M. Occhipinti, F.R. Di Pietro, L. Lionetto, M. Simmaco, P. Marchetti
Journal: Annals of Oncology (2016)
Predictive/prognostic value of circulating regulatory T cell subset in untreated non-small lung cancer patients
Authors: E.K. Vetsika, F. Koinis, A. Katsarou, M. Gioulbasani, D. Aggouraki, N. Kentepozidis, V. Georgoulias, A. Kotsakis
Journal: Annals of Oncology (2016)
Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.
Authors: Gianantonio Rosti, Fausto Castagnetti, Marilina Amabile, Nicoletta Testoni, Angela Poerio, Giulia Marzocchi, Massimo Breccia, Francesca Palandri, Tamara Intermesoli, Fabio Stagno, Giorgina Specchia, Elisabetta Abruzzese, Panagiota Giannoulia, Giuseppe Saglio, Fabrizio Pane, Francesca Rancati, Arnon Nagler, Ibrahim Haznedaroglu, Kimmo PorkKa, Henrik Hjorth-Hansen, Johan L. Nielsen, Bengt Simonsson, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2006)
Cloning of the Full-Length Gene of a Novel Human Acute Monocytic Leukemia Associated Antigen (MLAA-22) and Characterization of Its Functions
Authors: Wanggang Zhang, Liufang Gu, Aili He, Xingmei Cao, Yinxia Chen, Xiaorong Ma, Jie Liu, Pengyu Zhang
Journal: Blood (2011)
Evaluating cancer patient satisfaction before and after daily multidisciplinary care for thoracic surgery inpatients
Authors: M. D. Adolph, R. M. Taylor, P. M. Ross, A. M. Vaida, S. D. Moffatt-Bruce
Journal: Journal of Clinical Oncology (2009)

9605 Background: Significant subpopulations of cancer inpatients in the SUPPORT trial were dissatisfied with their pain control. (Desbiens, Wu et al. 1996) The hospitalized thoracic surgical patient is a person at risk for uncontrolled symptoms and burdens due to advanced cancer at time of presentation. Methods: This is a retrospective, observational, study of 1188 thoracic surgery patients undergoing elective surgical procedures for lung cancer at an NCI-approved cancer hospital over a 3-year period. Patients with primary and secondary lung cancer, undergoing elective thoracic surgery procedures were evaluated before (n=660, “Period 1”) and after (n=528, “Period 2”) an 8-month, daily, collaborative multidisciplinary Intervention Period to improve pain control and to facilitate transition for discharge. The collaborative process also identified thoracic surgical patients who needed more complex symptom management and additional support for advanced disease. Patient satisfaction with pain therapy and referrals to hospice were analyzed before and after the intervention period. Results: Pain satisfaction scores improved from baseline in each sequential period (Period 1 = 9.0 SD 1.71, Intervention Period = 9.4 SD 1.37, and Period 2 = 9.5 SD 1.03, p&lt;0.0001). The percentage of patients referred to hospice increased from 0.15% to 1.7% (p&lt;0.0001). Conclusions: Innovative collaboration between thoracic surgery specialists and a palliative medicine service improved patients’ satisfaction with pain control. The collaborative relationship resulted in an increase in referrals to hospice for patients with advanced cancer. These improvements were sustained by the thoracic surgery service after a daily collaborative intervention period ceased. No significant financial relationships to disclose.
High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action
Authors: Homer Adams, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, Saad Z Usmani, Torben Plesner, Sagar Lonial, Berris van Kessel-Welmers, Henk M. Lokhorst, Tuna Mutis, Niels W.C.J. van de Donk, A. Kate Sasser
Journal: Blood (2016)
Monocyte Chemotactic Response in Cancer Patients: A Discussion 01 Statistical Evaluation: Reply
Authors: Edward J. Leonard
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Monocyte Chemotactic Response in Cancer Patients: A Discussion 01 Statistical Evaluation: Reply Get access Edward J. Leonard, M. D. Edward J. Leonard, M. D. Tumor Antigen Section Biology Branch National Cancer InstituteBethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 4, April 1975, Page 1015, https://doi.org/10.1093/jnci/54.4.1015-a Published: 01 April 1975
Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy
Authors: D. Boucher, S. Hillier, D. Newsome, Y. Wang, D. Takemoto, Y. Gu, W. Markland, R. Hoover, R. Arimoto, J. Maxwell, S.Z. Fields, P. Charifson, M.S. Penney, K. Tanner
Journal: Annals of Oncology (2016)
PIK-ORL: A phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients (pts) with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platin and cetuximab or anti-EGFR-based therapy
Authors: J. Fayette, L. Digue, C. Ferlay, I. Treilleux, G. Garin, Q. Wang, C. Hebert, C. Even, D. Cupissol, S. Couchon-Thaunat, L. Jaouen, A. Guyennon, C. Le Tourneau, G. Lefebvre, A. Mailliez, M. Matias, M. Degardin, S. Tartas, G. Clapisson, D. Perol
Journal: Annals of Oncology (2016)
Possible prognostic value of local immunity cellular factors in primary and recurrent soft tissue sarcomas
Authors: E. Zlatnik, O. Kit, I. Novikova, T. Aliev, E. Nepomnyashchaya, T. Ausheva, O. Selyutina, I. Dashkova, L. Vashchenko, E. Andreyko, E. Kechedzhieva, I. Sidorenko, E. Velieva, L. Vladimirova
Journal: Annals of Oncology (2016)
Co-Transplantation of HLA-Haploidentical, Bone Marrow Derived Mesenchymal Stem Cells Prevents Graft Failure and Improves Hematological Recovery in T-Cell Depleted Haploidentical Stem Cell Transplantation.
Authors: Lynne M. Ball, Maria-Ester Bernardo, Helene Roelofs, Arjan Lankester, Angela Cometa, R. Maarten Egeler, Angela Cometa, Giovanna Giorgiani, Franco Locatelli, Willem E. Fibbe
Journal: Blood (2007)
Two-Stage Pharmacokinetic &amp; Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].
Authors: Alan F. List, Jeffrey E. Lancet, Magda Melchert, Hussein Saba, Richard Lush, Jian Yu, Nianhang Chen, Michele Schmidt, Robert Knight
Journal: Blood (2007)